IMVT Immunovant, Inc.
$29.42▲ +1.87%
Healthcare
Other
After hours
$29.30▼ -0.41%
Oct 28, 7:20 PM ET
Volume 1.24M
Avg Volume (10D) 1.33M
Key Metrics & Fundamentals
Market Cap
$6.08B
P/E Ratio
–
Div Yield
0.00%
52W Range
21.34 - 45.42
% vs 50 MA
-16.34%
% vs 200 MA
-8.11%
RSI-14
40.5
MACD Histogram
+0.3600
Beta (1Y vs SPY)
1.25
Free Cash Flow
-$124.41M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$160.23M
COGS
–
Operating Exp
$160.32M
Operating Income
-$160.32M
EBIT
-$160.32M
Pretax Income
-$153.22M
Net Income
-$153.22M
EPS (Diluted)
-0.75
Price & Volume History
Loading chart…
Recent News
Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
GlobeNewswire · Oct 21, 2026 7:00 AM ET
Immunovant (IMVT) Stock Looks Stretched On Book Value Alone
Simply Wall St. · Oct 20, 2026 10:14 AM ET
IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
Stocktwits · Oct 8, 2026 1:33 PM ET
Why Immunovant (IMVT) Is Down 10.3% After Halting IMVT-1402 Development in Cutaneous Lupus – And What's Next
Simply Wall St. · Sep 30, 2026 2:06 AM ET
Immunovant (IMVT) Just Gave Investors Something To Think About
Simply Wall St. · Sep 28, 2026 10:07 PM ET
Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months
MarketBeat · Sep 28, 2026 4:02 AM ET
Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case
Insider Monkey · Sep 27, 2026 10:40 AM ET
IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down
Zacks · Sep 24, 2026 11:50 AM ET
Lilly’s latest China drug deal; Immunovant’s setback in lupus
BioPharma Dive · Sep 24, 2026 10:14 AM ET
Roivant reports top-line data from IMVT-1402 CLE trial
Clinical Trials Arena · Sep 24, 2026 5:32 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See IMVT's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.